# A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatme

Source: https://onco.cc/trials/nct07229846/  
OnCo record `nct07229846` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of FOLFOXIRI, fOLFOX (5-FU, leucovorin, oxaliplatin), fOLFIRI (5-FU, leucovorin, irinotecan), capecitabine and other drugs in colorectal cancer, run by Yanqiao Zhang, not yet recruiting.

## Summary

A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation is a phase 2, interventional study registered as NCT07229846 by Yanqiao Zhang, with a registry enrolment figure of 30 participants, started 2026-02 and due to reach its primary completion in 2027-02. Interventions recorded: Aipalolitovorelizumab; XELOX + Bevacizumab; mFOLFOX + Bevacizumab; FOLFOXIRI + Bevacizumab; Oxaliplatin + Irinotecan + Capecitabine + Bevacizumab. Conditions listed: Colorectal Cancer. Primary outcome: Objective Response Rate. Colorectal eligibility wording from the registry: "Patients with histopathologically confirmed unresectable metastatic colorectal adenocarcinoma of MSS/pMMR type with known BRAF V600E mutation;". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07229846
- Phase: 2
- Setting: A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation
- Sponsor: Yanqiao Zhang
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT07229846: https://clinicaltrials.gov/study/NCT07229846

## Connected records

- cancers: [BRAF V600E-mutant colorectal cancer](https://onco.cc/cancers/braf-v600e-colorectal/), [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Platinum agents](https://onco.cc/technologies/platinum/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [Bevacizumab (glioblastoma use)](https://onco.cc/drugs/bevacizumab-glioma/), [Capecitabine](https://onco.cc/drugs/capecitabine/), [FOLFIRI (5-FU, leucovorin, irinotecan)](https://onco.cc/drugs/folfiri/), [FOLFOX (5-FU, leucovorin, oxaliplatin)](https://onco.cc/drugs/folfox/), [FOLFOXIRI (5-FU, leucovorin, oxaliplatin, irinotecan)](https://onco.cc/drugs/folfoxiri/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07229846.json